Navigation Links
Drugs used to tackle hospital-acquired infections can increase post-op complications
Date:10/31/2011

The introduction of new antibiotic regimes to tackle hospital-acquired infections, such as C. difficile, must take into account the possibility of increased infections following specific surgical procedures. That is the key finding of a study published in the November issue of the urology journal BJUI.

UK researchers from Addenbrooke's Hospital, Cambridge discovered that patients undergoing a standard surgical procedure to diagnose prostate cancer developed more than five times as many infective complications when a new standard antibiotic regime was introduced.

These included a number of cases of sepsis and one case of septic shock, which they describe as a highly significant finding.

"The change, based on national guidance, reflected concerns that C. difficile rates were being driven by the widespread use of broad-spectrum antibiotics such as ciprofloxacin" explains departmental lead and senior author Professor David Neal. "The new regime was introduced on the proviso that both the hospital-acquired infection rates and post-operative infection rates would be closely monitored.

"Given that there were no cases of C. difficile recorded in our study, but post-operative infection rates increased significantly, the decision was taken to revert back to the original regime."

Records for 709 consecutive patients who received transrectal ultrasound-guided prostate biopsy surgery (TRUSP Bx) over a period of 20 months were studied. These showed that:

  • Only 2.4 per cent of the 454 patients treated with the original regime of prophylaxis with ciprofloxacin developed an infective complication within four weeks of surgery and four (0.9 per cent) were admitted for complications.

  • 12.9 per cent of the patients treated with the new regime of prophylaxis with co-amoxiclav and gentamicin developed an infective complication within four weeks of surgery. Twelve patients (4.7 per cent) were admitted for complications.

  • Seven of the 12 patients readmitted after being treated with the new regime were admitted with sepsis - in which the bloodstream is overwhelmed by bacteria - and a further patient had septic shock, which required inotropic support for 24 hours. None of the patients on the original regime had these very serious complications.

  • None of the patients developed C. difficile within one month of receiving antibiotics.

  • Reintroducing the original regime led to a fall in infective complications.

"Even though TRUSP Bx is a common urological procedure there are currently no national guidelines regarding antibiotic prophylaxis and local protocols vary widely across the UK" says Professor Neal. "However, the importance of using prophylaxis for a biopsy, to reduce the occurrence of infective complications following surgery, has been well documented.

"This is the first study to compare the use of co-amoxiclav and gentamicin with the use of ciprofloxacin for TRUSP Bx. Patients given the original ciprofloxacin regime experienced significantly fewer infective complications than those on the new regime and this audit study supports the use of locally determined prophylactic regimes for this procedure."

The authors stress that antibiotic prophylaxis needs to reflect the local situation, both in terms of tissue penetration, the organisms encountered and their susceptibilities and the local C. difficile rates. They add that any changes also need to be subject to frequent review.

"Any alteration to existing departmental antibiotic policies should be linked to strong clinical evidence, because such changes may potentially result in significant ill health and potential harm, as well as the financial burden of treating new complications" concludes Professor Neal.


'/>"/>

Contact: Annette Whibley
annette.wizard@gmail.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Some People With Alzheimers Take Conflicting Drugs
2. Study indicates nanoparticles could help pain-relieving osteoarthritis drugs last longer
3. Many Alzheimers patients get drugs with opposing effects
4. Some Asthma Drugs Raise Risk of Complications, Especially in Kids: Study
5. New anti-inflammatory drugs might help avoid side effects of steroids
6. Double duty for blood pressure drugs: how they could revolutionize how we treat valve disease
7. Are acid-suppressing drugs prescribed too often in infants?
8. Hypertension, Not Blood Pressure Drugs, Linked to Birth Defects
9. Antiviral drugs may slow Alzheimers progression
10. Tests to catch the makers of dangerous legal high designer drugs
11. $8.4 million grant supports health information exchange and research on Alzheimers drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... ... A study by the founder of the Buckingham Center for Facial ... recently published in the American Journal of Cosmetic Surgery. “The Effects of an Antistick ... on the use of Electro Lube during the facelift procedure. The journal, a publication ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the New England Journal of Medicine and NEJM Journal Watch, announces the release ... Review was created by a panel of pediatricians from leading medical centers. The ...
(Date:3/27/2017)... Cranbury, NJ (PRWEB) , ... March 27, 2017 ... ... publication of cutting-edge news, research and conference coverage on veterinary medicine, announces the ... The inaugural issue will be packaged with the April edition of American Veterinarian™. ...
(Date:3/27/2017)... ... March 27, 2017 , ... Advantexe ... announced the launch of a new research study, The Business Readiness Report. The ... execute that strategy, and the actual success of achieving individual and company goals. ...
(Date:3/27/2017)... ... 2017 , ... The Association of Healthcare and Value Analysis ... first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will provide the Keynote ... analysis professionals have a ‘seat at the table’ with clinical committees when it ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  Twist Bioscience, a ... synthesis, today announced that it raised an additional $33 ... of $166 million. "It is an ... expand our reach and continue to deliver industry-leading gene ... market segments," commented Emily M. Leproust, Ph.D., CEO of ...
(Date:3/27/2017)... 2017 Cota Healthcare, the leading ... medicine, today announced the signing of a ... to help improve clinical and cost outcomes ... part of this agreement, which expands significantly ... January 2016, teams from across Novartis Pharmaceuticals ...
(Date:3/27/2017)...   Genprex, Inc. , a privately held, clinical-stage biopharmaceutical company ... the Company,s Chief Operating Officer, is scheduled to present a corporate ... 5th Annual Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 ... ... 24th Annual Future Leaders in Biotech Industry – Friday, April 7, ...
Breaking Medicine Technology: